{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:36:02Z","timestamp":1770078962528,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.pnpbp.2005.08.015","type":"journal-article","created":{"date-parts":[[2005,10,24]],"date-time":"2005-10-24T18:12:38Z","timestamp":1130177558000},"page":"131-137","source":"Crossref","is-referenced-by-count":24,"title":["Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome"],"prefix":"10.1016","volume":"30","author":[{"given":"Patrick","family":"Lemoine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imane","family":"Kermadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Garcia-Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo P.","family":"Garay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Dib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2005.08.015_bib1","first-page":"5","article-title":"Utilisation d'un nouveau neuroleptique s\u00e9datif, la cyam\u00e9mazine (Tercian\u00ae) dans l'alcoolisme","volume":"5","author":"Ajzenberg","year":"1973","journal-title":"Psychol. M\u00e9d."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib2","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s002130050010","article-title":"5-HT3- and receptor 5-HT2C-receptor antagonist properties of cyamemazine: significance for its clinical anxiolytic activity","volume":"147","author":"Alvarez-Guerra","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.08.015_bib3","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"1994"},{"key":"10.1016\/j.pnpbp.2005.08.015_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF02247359","article-title":"Increased 5-HT release mediates the anxiogenic response during benzodiazepine withdrawal: a review of supporting neurochemical and behavioural evidence","volume":"112","author":"Andrews","year":"1993","journal-title":"Psychopharmacologia (Berl)"},{"key":"10.1016\/j.pnpbp.2005.08.015_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1192\/bjp.157.2.232","article-title":"A double blind placebo-controlled study of buspirone in diazepam withdrawal in chronic benzodiazepine users","volume":"157","author":"Ashton","year":"1990","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.08.015_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/0924-9338(96)80322-1","article-title":"Neuroleptic malignant syndrome following tiapride treatment of clonazepam withdrawal","volume":"10","author":"Bobolakis","year":"1995","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0166-4328(01)00238-8","article-title":"Cyamemazine as an anxiolytic drug on the elevated plus maze and light\/dark paradigm in mice","volume":"124","author":"Bourin","year":"2001","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib8","unstructured":"Declaration of Helsinki, Hong Kong amendment (September 1989)."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib9","unstructured":"European Forum for Good Clinical Practice. \u201cEuropean Guidelinesnext term for Auditing Independent Ethics Committees.\u201d 2001. Available from: URL: http:\/\/www.efgcp.org."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib10","first-page":"954","article-title":"Analyse des prescriptions de neuroleptiques dans cinq centres hospitaliers sp\u00e9cialis\u00e9s. Comparaisons entre prescriptions hospitali\u00e8res et prescriptions de sortie","volume":"76","author":"Gury","year":"2000","journal-title":"Inf. Psychiatr."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0006-2952(02)01515-0","article-title":"Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes","volume":"65","author":"Hameg","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib12","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety state by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychiatr."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.fbp.0000082131.08343.0e","article-title":"Physical dependence in baboons chronically treated with low and high doses of diazepam","volume":"14","author":"Kaminski","year":"2003","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.comppsych.2003.12.007","article-title":"Determination of the main risk factors for benzodiazepine dependence using a multivariate and multidimensional approach","volume":"45","author":"Kan","year":"2004","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.08.015_bib15","series-title":"Serotonin1A Receptors in Depression and Anxiety","first-page":"171","article-title":"Promising anxiolytics? A new class of drugs: the azapirones","author":"Keppel Hesselink","year":"1992"},{"issue":"Suppl. 3","key":"10.1016\/j.pnpbp.2005.08.015_bib17","doi-asserted-by":"crossref","first-page":"161S","DOI":"10.1016\/0924-9338(96)80098-8","article-title":"Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months","volume":"10","author":"Lemoine","year":"1995","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib18","first-page":"170","article-title":"Chronic benzodiazepine administration: I. Tolerance is associated with benzodiazepine receptor down-regulation and decreased gamma-aminobutyric acid receptor function","volume":"246","author":"Miller","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib19","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s002130050785","article-title":"Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in mice","volume":"140","author":"Naassila","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2005.08.015_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/med.2610100302","article-title":"The discovery and development of buspirone: a new approach to the treatment of anxiety","volume":"10","author":"New","year":"1990","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/978-1-349-11922-6_9","article-title":"Selective ligands for benzodiazepine receptors: recent developments","volume":"2","author":"Nutt","year":"1990","journal-title":"Curr. Asp. Neurosci."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.addbeh.2004.01.001","article-title":"Psychological distress and adaptational problems associated with benzodiazepine withdrawal and outcome: a replication","volume":"29","author":"O'Connor","year":"2004","journal-title":"Addict. Behav."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4088\/PCC.v03n0303","article-title":"Medications for the treatment of sleep disorders: an overview","volume":"3","author":"Pagel","year":"2001","journal-title":"Prim. Care Companion J. Clin. Psychiat."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00210-002-0665-4","article-title":"Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine","volume":"367","author":"Peinado","year":"2003","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib25","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/(SICI)1099-1166(199909)14:9<754::AID-GPS15>3.0.CO;2-E","article-title":"A programme for short-term withdrawal from benzodiazepines in geriatric hospital inpatients: success rate and effect on subjective sleep quality","volume":"14","author":"Petrovic","year":"1999","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.08.015_bib26","first-page":"323","article-title":"Un questionnaire d'auto\u00e9valuation de la symptomatologie d\u00e9pressive, le questionnaire QDZA. (QDZA. A self-administered questionnaire of depressive symptomatology)","volume":"34","author":"Pichot","year":"1984","journal-title":"Rev. Psychol. Appl."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1381612023396636","article-title":"The experimental pharmacotherapy of benzodiazepine withdrawal","volume":"8","author":"Podhorna","year":"2002","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jpsychires.2003.10.003","article-title":"Chronic benzodiazepine usage and withdrawal in insomnia patients","volume":"38","author":"Poyares","year":"2004","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib29","first-page":"967","article-title":"Cyam\u00e9mazine: traitement symptomatique des dimensions anxieuses, impulsives et agressives","volume":"10","author":"Radat","year":"1995","journal-title":"Inf. Psychiatr."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib30","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1001\/archpsyc.1990.01810220015002","article-title":"Long-term therapeutic use of benzodiazepines: I. Effects of abrupt discontinuation","volume":"47","author":"Rickels","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2005.08.015_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0022-3956(93)90024-V","article-title":"Adjunctive treatment of benzodiazepine discontinuation syndromes: a review","volume":"27","author":"Roy-Byrne","year":"1993","journal-title":"J. Psychiatr. Res."},{"issue":"Suppl. 3","key":"10.1016\/j.pnpbp.2005.08.015_bib32","doi-asserted-by":"crossref","first-page":"145S","DOI":"10.1016\/0924-9338(96)80096-4","article-title":"Withdrawal from benzodiazepines by initially switching to zopiclone","volume":"10","author":"Shapiro","year":"1995","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.pnpbp.2005.08.015_bib33","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0924-977X(96)88043-6","article-title":"The pharmacological management of benzodiazepine withdrawal","volume":"6","author":"Schweizer","year":"1996","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"Suppl. 20","key":"10.1016\/j.pnpbp.2005.08.015_bib34","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.08.015_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1192\/bjp.178.4.317","article-title":"Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group","volume":"178","author":"Zitman","year":"2001","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2005.08.015_bib36","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0033-3182(71)71479-0","article-title":"A rating instrument for anxiety disorders","volume":"12","author":"Zung","year":"1971","journal-title":"Psychosomatics"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584605002782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584605002782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T15:57:52Z","timestamp":1548086272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584605002782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0278584605002782"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2005.08.015","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}